stabilis - monographie - imipenem - cilastatin sodium
TRANSCRIPT
StabilisImipenem - cilastatin sodium
Tradename
Arzomeba ChileBacqure Ecuador, Morocco, PeruBetatrexil EcuadorCilanem ChileCilapem TurkeyConet SloveniaGimipen ColombiaImacina ChileImipen ItalyImistatin ArgentinaLinataz ColombiaPerloyem ArgentinaPrimaxin Australia, Canada, Great Britain,
Greece, New Zealand, Peru, UnitedStates of America
Silanem TurkeySilpen ChileTenacid ItalyTesilan ColombiaTienam Belgium, Chile, Colombia, Croatia,
Denmark, Ecuador, Egypt, Finland,France, Germany, Hungary, Iran,Ireland, Italy, Luxembourg, Malaysia,Mexico, Morocco, Netherlands,Norway, Peru, Poland, Portugal,Republic of South Africa, Romania,Saudi Arabia, Spain, Sweden,Switzerland, Thailand, Tunisia, Turkey,United Arab Emirates
Zienam Argentina, Austria, Germany,Venezuela
Stability in solutions
2.5 mg/ml 4°C 72 21
2.5 & 5 mg/ml 25°C 9 21
5 mg/ml 4°C 48 21
www.stabilis.org - 14/07/2022 01:11 - Page 1
2.5 mg/ml 4°C 72 21
2.5 & 5 mg/ml 25°C 9 21
5 mg/ml 4°C 48 21
2.5 mg/ml 25°C 6 21
2.5 & 5 mg/ml 4°C 24 21
5 mg/ml 25°C 3 21
2.5 mg/ml 25°C 6 21
2.5 & 5 mg/ml 4°C 24 21
5 mg/ml 25°C 3 21
2.5 & 5 mg/ml 25°C 3 21
2.5 & 5 mg/ml 4°C 24 21
2,5 mg/ml 22°C 24 1067
2,5 mg/ml 4°C 24 1067
2,5 & 5 mg/ml 4°C 3 1811
5 mg/ml 2-8°C 8 4298
5 mg/ml 23-27°C 4 4298
5 mg/ml 25°C 24 604
5 mg/ml 4°C 3 604
8 mg/ml 25°C 3 2042
8 mg/ml 37°C 2 2042
Factors which affect stability
8981103
21150
-20°C 21
21
Compatibility
Imipenem - cilastatin sodium 21Imipenem - cilastatin sodium : 0.5 mg/ml 1103
www.stabilis.org - 14/07/2022 01:11 - Page 2
Imipenem - cilastatin sodium 3530Imipenem - cilastatin sodium : 5 mg/ml 4440Imipenem - cilastatin sodium : 10 mg/ml 1415Imipenem - cilastatin sodium : 5/5 mg/mlAciclovir sodium : 5 mg/ml 336
Imipenem - cilastatin sodium : 5 mg/ml 898Imipenem - cilastatin sodium : 10 mg/ml 301Imipenem - cilastatin sodium 3985Imipenem - cilastatin sodium : 10 mg/mlAllopurinol sodium : 3 mg/ml 307
Imipenem - cilastatin sodium : 10 mg/mlAmifostine : 10 mg/ml 3
Imipenem - cilastatin sodiumAmikacin sulfate 3549
Imipenem - cilastatin sodium : 5 mg/mlAmiodarone hydrochloride : 6 mg/ml 1611
Imipenem - cilastatin sodium : 4/4 mg/mlAmoxicillin sodium : 8 mg/ml 2349
Imipenem - cilastatin sodium : 10 mg/mlAmphotericin B cholesteryl sulfate complex : 0.83 mg/ml 921
Imipenem - cilastatin sodium : 5 mg/mlAnidulafungin : 0.5 mg/ml 1982
Imipenem - cilastatin sodium : 5 mg/mlAzithromycine : 2 mg/ml 1800
Imipenem - cilastatin sodium : 10 mg/mlAztreonam : 40 mg/ml 99
Imipenem - cilastatin sodium : 5 mg/mlBlinatumomab : 0.125 & 0.375 µg/ml 3976
Imipenem - cilastatin sodium : 5 mg/mlCaspofungin acetate : 0,7 mg/ml 2247
Imipenem - cilastatin sodium : 10 mg/mlCefiderocol sulfate tosylate : 20 mg/mL 4528
Imipenem - cilastatin sodium : 50 mg/mlCefoxitin sodium : 100 mg/ml 4389
Imipenem - cilastatin sodium : 5/5 mg/mlCeftolozane / tazobactam : 10/5 mg/ml 3828
Imipenem - cilastatin sodium : 10 mg/mlCisatracurium besylate : 0.1 >> 5 mg/ml 299
Imipenem - cilastatin sodium : 5/5 mg/mlColistin mesilate sodium : 1.5 mg/ml 3997
Imipenem - cilastatin sodium : 9.94/9.94 mg/mlDefibrotide : 8 mg/ml 3728
Imipenem - cilastatin sodium : 9.94/9.94 mg/mlDefibrotide : 8 mg/ml 3728
Imipenem - cilastatin sodium : 5 mg/mlDiltiazem hydrochloride : 5 mg/ml 198
Imipenem - cilastatin sodium : 10 mg/mlDocetaxel : 0.9 mg/ml 1754
www.stabilis.org - 14/07/2022 01:11 - Page 3
Imipenem - cilastatin sodium : 5 mg/mlEnalaprilate : 0.0125 mg/ml 1703
Imipenem - cilastatin sodium : 5/5 mg/mlEravacycline : 0,6 mg/ml 4434
Imipenem - cilastatin sodiumErythromycin lactobionate 3674
Imipenem - cilastatin sodium : 10 mg/mlEtoposide phosphate : 5 mg/ml 1410
Imipenem - cilastatin sodium : 10 mg/mlFamotidine 397
Imipenem - cilastatin sodium : 10 mg/mlFilgrastim : 30 µg/ml 244
Imipenem - cilastatin sodium : 5/5 mg/mlFilgrastim : 40 µg/ml 104
Imipenem - cilastatin sodium : 10 mg/mlFluconazole : 2 mg/ml 496
Imipenem - cilastatin sodium : 5 mg/mlFludarabine phosphate : 1 mg/ml 492
Imipenem - cilastatin sodium : 10 mg/mlFoscarnet sodium : 24 mg/ml 73
Imipenem - cilastatin sodium : 5 mg/mlFoscarnet sodium : 24 mg/ml 1135
Imipenem - cilastatin sodium : 5/5 mg/mlFosfomycin : 30 mg/ml 4055
Imipenem - cilastatin sodium : 5/5 mg/mlGallium nitrate : 1 mg/ml 91
Imipenem - cilastatin sodium : 10 mg/mlGemcitabine hydrochloride : 10 mg/ml 1423
Imipenem - cilastatin sodium : 10 mg/mlGranisetron hydrochloride : 0.05 mg/ml 182
Imipenem - cilastatin sodium : 5 mg/mlIdarubicin hydrochloride : 1 mg/ml 491
Imipenem - cilastatin sodium : 5 mg/mlInsulin aspart : 1 UI/ml 1508
Imipenem - cilastatin sodium : 5/5 mg/mlIsavuconazonium sulfate : 1.5 mg/ml 3829
Imipenem - cilastatin sodium : 10 mg/mlLansoprazole : 0.55 mg/ml 1625
Imipenem - cilastatin sodium : 10 mg/mlLinezolid : 2 mg/ml 1925
Imipenem - cilastatin sodium : 5 mg/mlLorazepam : 0.33 mg/ml 186
Imipenem - cilastatin sodium : 10 mg/mlMelphalan : 0.1 mg/ml 169
Imipenem - cilastatin sodium : 50 mg/mlMeropenem : 50 mg/ml 4319
Imipenem - cilastatin sodium : 5 mg/mlMidazolam hydrochloride : 5 mg/ml 186
Imipenem - cilastatin sodium : 5 mg/mlOndansetron hydrochloride : 1 mg/ml 334
Imipenem - cilastatin sodium : 5 mg/mlPethidine hydrochloride : 10 mg/ml 62
www.stabilis.org - 14/07/2022 01:11 - Page 4
Imipenem - cilastatin sodium : 2,5 mg/mlPhloroglucinol : 2,5 mg/ml 3791
Imipenem - cilastatin sodium : 5/5 mg/mlPlazomicin sulfate : 24 mg/ml 4145
Imipenem - cilastatin sodium : 10 mg/mlPropofol : 10 mg/ml 300
Imipenem - cilastatin sodium : 5 mg/mlPropofol 660
Imipenem - cilastatin sodium : 10 mg/mlRemifentanil hydrochloride : 25 & 250 µg/ml 59
Imipenem - cilastatin sodium : 5 mg/mlSargramostim : 10 µg/ml 335
Imipenem - cilastatin sodium : 250 & 500 mg/mlSodium bicarbonate : 50 mg/ml 21
Imipenem - cilastatin sodium : 10 mg/mlTacrolimus : 1000 µg/ml 479
Imipenem - cilastatin sodium : 5/5 mg/mlTedizolid phosphate : 0.8 mg/ml 3827
Imipenem - cilastatin sodium : 5/5 mg/mlTelavancin hydrochloride : 7.5 mg/ml 3254
Imipenem - cilastatin sodium : 5/5 mg/mlTelavancin hydrochloride : 7,5 mg/ml 3254
Imipenem - cilastatin sodium : 5/5 mg/mlTelavancin hydrochloride : 7.5 mg/ml 3254
Imipenem - cilastatin sodiumTemocilline 4470
Imipenem - cilastatin sodium : 10 mg/mlTeniposide : 0.1 mg/ml 905
Imipenem - cilastatin sodium : 10 mg/mlThiotepa : 1 mg/ml 249
Imipenem - cilastatin sodium : 5/5 mg/mlVasopressin : 0.2 UI/ml 2017
Imipenem - cilastatin sodium : 10 mg/mlVinorelbine tartrate : 1 mg/ml 84
Imipenem - cilastatin sodium : 5 mg/mlZidovudine : 4 mg/ml 337
Route of administration
References
Type Publication3 Journal Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
www.stabilis.org - 14/07/2022 01:11 - Page 5
21 Journal Bigley FP, Forsyth RJ, Henley MW.Compatibility of imipenem-cilastatin sodium with commonly used intravenous solutions.Am J Hosp Pharm 1986 ; 43: 2803-2809.
59 Journal Trissel LA, Gilbert DL, Martinez JF, Kim MC.Compatibility of remifentanil hydrochloride with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 2192-2196.
62 Journal Pugh CB, Pabis DJ, Rodriguez C.Visual compatibility of morphine sulfate and meperidine hydrochloride with other injectable drugs during simulatedY-site injection.Am J Hosp Pharm 1991 ; 48: 123-125.
73 Journal Lor E, Takagi J.Visual compatibility of foscarnet with other injectable drugs.Am J Hosp Pharm 1990 ; 47: 157-159.
84 Journal Trissel LA, Martinez JF.Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugsduring simulated Y-site injection.Am J Hosp Pharm 1994 ; 51: 495-499.
91 Journal Lober CA, Dollard PA.Visual compatibility of gallium nitrate with selected drugs during Y-site injection.Am J Hosp Pharm 1993 ; 50: 1208-1210.
99 Journal Trissel LA, Martinez JF.Compatibility of aztreonam with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
104 Journal Hall PD, Yui D, Lyons S, Bosso JA.Compatibility of filgrastim with selected antimicrobial drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 185-189.
150 Journal Aujoulat P, Coze C, Braguer D, Raybaud C.Physicochemical compatibility of methotrexate with co-administered drugs during cancer chemotherapy regimens.J Pharm Clin 1993 ; 12: 31-35.
169 Journal Trissel LA, Martinez JF.Physical compatibility of melphalan with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1993 ; 50: 2359-2363.
182 Journal Trissel LA, Gilbert DL, Martinez JF.Compatibility of granisetron hydrochloride with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 56-60.
186 Journal Swart EL, Mooren RAG, Van Loenen AC. Compatibility of midazolam hydrochloride and lorazepam with selected drugs during simulated Y-siteadministration.Am J Health-Syst Pharm 1995 ; 52: 2020-2022.
198 Journal Gayed AA, Kheshary PR, Hinkle RL.Visual compatibility of diltiazem injection with various diluents and medications during simulated Y-site injection.Am J Health-Syst Pharm 1995 ; 52: 516-520.
244 Journal Trissel LA, Martinez JF.Compatibility of filgrastim with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1994 ; 51: 1907-1913.
249 Journal Trissel LA, Martinez JF.Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
299 Journal Trissel LA, Martinez JF, Gilbert DL.Compatibility of cisatracurium besylate with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1735-1741.
www.stabilis.org - 14/07/2022 01:11 - Page 6
300 Journal Trissel LA, Gilbert DL, Martinez JF.Compatibility of propofol injectable emulsion with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1287-1292.
301 Journal Trissel LA, Gilbert DL, Martinez JF, Baker MB, Walter WV, Mirtallo JM.Compatibility of parenteral nutrient solutions with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 1997 ; 54: 1295-1300.
307 Journal Trissel LA, Martinez JF.Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 Journal Trissel LA, Tramonte SM, Grilley BJ.Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 988-992.
335 Journal Trissel LA, Bready BB, Kwan JW, Santiago NM.Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs duringsimulated Y-site injection.Am J Hosp Pharm 1992 ; 49: 402-406.
336 Journal Forman JK, Lachs JR, Souney PF.Visual compatibility of acyclovir sodium with commonly used intravenous drugs during simulated Y-site injection.Am J Hosp Pharm 1987 ; 44: 1408-1409.
337 Journal Bashaw ED, Amantea MA, Minor JR, Galleli JF.Visual compatibility of zidovudine with other drugs during simulated Y-site administration.Am J Hosp Pharm 1988 ; 45: 2532-2533.
397 Journal Fong PA, Ward J.Visual compatibility of intravenous famotidine with selected drugs.Am J Hosp Pharm 1989 ; 46: 125-126.
479 Journal Min DI, Brown T, HWang GC.Visual compatibility of tacrolimus with commonly used drugs during simulated Y-site injection.Am J Hosp Pharm 1992 ; 49: 2964-2966.
491 Journal Turowski RC, Durthaler JM.Visual compatibility of idarubicin hydrochloride with selected drugs during simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 2181-2184.
492 Journal Trissel LA, Parks NPT, Santiago NM.Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugsduring simulated Y-site injection.Am J Hosp Pharm 1991 ; 48: 2186-2189.
496 Journal Lor E, Sheybani T, Takagi J.Visual compatibility of fluconazole with commonly used injectable drugs during simulated Y-site administration.Am J Hosp Pharm 1991 ; 48: 744-746.
604 Manufacturer Stabilité des médicaments dans l'Intermate® SV50, 100, 200Baxter 1998
660 Journal Michaels MR, Stauffer GL, Haas DP.Propofol compatibility with other intravenous drug products - Two new methods of evaluating IV emulsioncompatibility.Ann Pharmacotherapy 1996 ; 30: 228-232.
898 Journal Zaccardelli DS, Sanders Kromarik C, Wolk R, Khalidi N.Stability of imipenem and cilastatin sodium in total parenteral nutrient solution.JPEN 1990 ; 14: 306-309.
905 Journal Trissel LA, Martinez JF.Screening teniposide for Y-site physical incompatibilities.Hosp Pharm 1994 ; 29: 1010-1017.
www.stabilis.org - 14/07/2022 01:11 - Page 7
921 Journal Trissel LA, Gilbert DL, Martinez JF.Incompatibility and compatibility of amphotericin B cholesteryl sulfate complex with selected other drugs duringsimulated Y-site administration.Hosp Pharm 1998 ; 33: 284-292.
1067 Journal Zeidler C, Dettmering D, Schrammel W, Spieteller M.Compatibility of various drugs used in intensive care medicine in polyethylene, PVC and glass infusion containers.EJHP 1999 ; 5: 106-110.
1103 Journal Fox AS, Boyer KM, Sweeney HM.Antibiotic stability in a pediatric parenteral alimentation solution.J Pediatr 1988 ; 112: 813-817.
1135 Journal Baltz JK, Kennedy P, Minor JR, Gallelli J.Visual compatibility of foscarnet with other injectable drugs during simulated Y-site administration.Am J Hosp Pharm 1990 ; 47: 2075-2077.
1410 Journal Trissel LA, Martinez JF, Simmons M.Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.J Am Pharm Assoc 1999 ; 39: 141-145.
1415 Journal Trissel L.A, Gilbert D.L, Martinez J.F, Baker M.B, Walter W.V, Mirtallo J.M.Compatibility of medications with 3-in-1 parenteral nutrition admixtures.JPEN 1999 ; 23: 67-74.
1423 Journal Trissel LA, Martinez JF, Gilbert DL.Compatibility of gemcitabine hyrochloride with 107 selected drugs during simulated Y-site injection.J Am Pharm Assoc 1999 ; 39: 514-518.
1508 Journal Voirol P, Berger-Gryllaki M, Pannatier A, Eggimann P, Sadeghipour F.Visual compatibility of insulin aspart with intravenous drugs frequently used in ICU.EJHP 2015 ;22:123-124.
1611 Journal Chalmers JR, Bobek MB, Militello MA.Visual compatibility of amiodarone hydrochloride injection with various intravenous drugs.Am J Health-Syst Pharm 2001 ; 58: 504-506.
1625 Journal Trissel LA, Saenz C, Williams YW, Ingram D.Incompatibilities of lansoprazole injection with other drugs during simulated Y-site coadministration.Int J Pharm Compound 2001 ; 5: 314-321.
1703 Journal Schuster F, Bernard R.Kompatibilität von enalaprilat i.v. mit ausgewählten arzneimitteln.Krankenhauspharmazie 1995 ; 16: 101-103.
1754 Journal Trissel LA, Gilbert DL, Wolkin AC.Compatibility of docetaxel with selected drugs during simulated Y-site administration.Int J Pharm Compound 1999 ; 3: 241-244.
1800 Journal Voytilla KL, Tyler LS, Rusho WJ.Visual compatibility of azithromycin with 24 commonly used drugs during simulated Y-site delivery.Am J Health-Syst Pharm 2002 ; 59: 853-855.
1811 Journal Trissel LA, Xu QA.Stability of imipenem-cilastatin sodium in autodose infusion system bags.Hosp Pharm 2003 ; 38: 130-134.
1925 Journal Trissel LA , Williams KY, Gilbert DL.Compatibility screening of linezolid injection during simulated Y-site administration with other drugs and infusionsolutions.J Am Pharm Assoc 2000 ; 40: 515-519.
1982 Journal Trissel LA, Ogundele AB.Compatibility of anidulafungin with other drugs during simulated Y-site administration.Am J Health-Syst Pharm 2005 ; 62: 834-837.
2017 Journal Barker B, Feddema S, Rusho WJ, Dengg R.Visual compatibility of vasopressin with other injectable drugs.Am J Health-Syst Pharm 2005 ; 62: 1969-1976.
www.stabilis.org - 14/07/2022 01:11 - Page 8
2042 Journal Viaene E, Chanteux H, Servais H, Mingeot-Leclerq MP, Tulkens PM.Comparative stability studies of antipseudomonal ß-lactams for potential administration through portable elastomericpumps (home therapy for cystic fibrosis patients) and motor-operated syringes (intensive care units).Antimicrob Agents Chemother 2002 ; 46: 2327-2332.
2247 Journal Chan P, Heatherly K, Kupiec T.C, Trissel L.A.Compatibility of caspofungin acetate injection with other drugs during simulated Y-site coadministration.Int J Pharm Compound 2008 ; 12, 3: 276-278.
2349 Journal Pourroy B, Milano Bausset E, Boulamery A, Gauthier Villano L, Braguer B.Incompatibility of imipenem–cilastatin and amoxicillin Am J Health-Syst Pharm 2009 ; 66: 1253-1254.
3254 Journal Housman S.T, Tessier P.R, Nicolau D.P, Kuti J.L.Physical compatibility of telavancin hydrochloride with select i.v. drugs during simulated Y-site administration Am J Health-Syst Pharm 2011 ; 68: 2265-2270.
3530 Manufacturer Imipenem/Cilastatin – Summary of Product CharacteristicsHospira 2013
3549 Manufacturer Amikacine B Braun - Résumé des caractéristiques du produit.B Braun 2012
3674 Manufacturer Erythromycin lactobionate - Summary of Product CharacteristicsPanPharma 2016
3728 Journal Correard F, Savry A, Gauthier-Villano L, Pisano P, Pourroy B.Visual compatibility of defibrotide with selected drugs during simulated Y-site administration.Am J Health-Syst Pharm 2014 ; 71: 1288-1291.
3791 Poster Sadou Yaye H, Burtet E, Hamel C, Aljhni R, Gard C, Tilleul P.Étude de la compatibilité physico-chimique du phloroglucinol injectable durant les mélanges au sein des tubulures enY.Apifh Congress, Paris November 2014 2014
3827 Poster Ghazi I.M, Hamada Y, Nicolau D.P.Compatibility of tedizolid phosphate with selected intravenous drugs via simulated Y-site conditions.ASHP Midyear 2015 2015
3828 Poster Thabit A.K, Hamada Y, Nicolau D.P.Ceftozolane/tazobactam physical compatibility during simulated Y-site administration.ASHP Midyear 2015 2015
3829 Poster So W, Kim L, Thabit A.K, Nicolau D.P, Kuti J.L.Compatibility of isavunazonium sulfate during simulated Y-site administration.ASHP Midyear 2015 2015
3976 Journal Du Repaire T, Vigne P, Guedon A, Gauthier-Villano L, Bertault Peres P, Pourroy B.Visual compatibility of blinatumomab with selected co-administrated drugs during simulated Y-site administration.Am J Health-Syst Pharm 2017 ; 74,16 : 1217-1218
3985 Poster Manai M., Soussi M.A., Lazreg O., Drira C., Ben Tekaya S. et Razgallah Khrouf M.Compatibilité physique entre médicaments injectables et nutrition parentérale pédiatrique : Evaluation in-vitro.Hopipharm Congress 2017 - Nancy 2017
3997 Journal Katip W.Visual compatibility of colistin injection with other antibiotics during simulated Y-site administration. Am J Health-Syst Pharm 2017 ; 74:14 : 1099-1102
4055 Journal Monogue M, Almarzoky Abuhussain S, Kuti J, Nicolau D.Physical compatibility of fosfomycin for injection with select i.v. drugs during simulated Y-site administration.Am J Health-Syst Pharm 2018 , 75, 1:36-44
4145 Journal Asempa T.E, Avery L.M, Kidd J.M, Kuti J.L, Nicolau D.P.Physical compatibility of plazomicin with select i.v. drugs during simulated Y-site administration.Am J Health-Syst Pharm 2018 ;75,14:1048-1056
www.stabilis.org - 14/07/2022 01:11 - Page 9
4298 Journal Fabio de Souza Barbosa F, Capra Pezzi L, Tsao M, Franco de Oliveira T, Dias Macedo S.M, Schapoval E.E.S,Mendez A.S.L.Stability and degradation products of imipenem applying High-Resolution Mass Spectrometry: an analytical studyfocused on solutions for infusion.Biomed Chromatogr 2019 ; 33, 4:e4471
4319 Journal Lessard J-J, Caron E, Schérer H, Forest J-M, Leclair G.Compatibility of Y-site Injection of Meropenem Trihydrate With 101 Other Injectable Drugs.Hosp Pharm 2020 ; 55, 5: 332-337.
4389 Journal Côté K, Correal F, Metras M.E, Friciu M, Forest J.M, Leclair G.Compatibilité physique des médicaments administrés en Y aux soins intensifs, en particulier la dexmédétomidine, lelévosimendan et la kétamine.Pharmactuel 2019 ;52,4:206-213
4434 Journal Avery L.M, Chen, I.H, Reyes, S, Nicolau, D.P, Kuti J.L.Assessment of the Physical Compatibility of Eravacycline and Common Parenteral Drugs During Simulated Y-siteAdministration.Clin Ther 2019 ; 41, 10: 2162-2170.
4440 Journal Omotani S, Aoe M, Esaki S, Nagai K, Hatsuda Y, Mukai J, Teramachi H, Myotoku M.Compatibility of Intravenous Fat Emulsion with Antibiotics for Secondary Piggyback Infusion.Ann Nutr Metab 2018 ; 73: 227-233.
4470 Journal Claeysoone K, Basma V, Hens R, Van Bambeke F, de Jongh R, Tulkens P.Continuous versus intermittent infusion of temocillin in intensive care unit patient.Critical care 2005 ; 9(Suppl 1) P37
4528 Journal Lu J, Liu Q, Kupiec T, Vail H, Lunch L, Fam D, Vu N. Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration.Int J Pharm Compound 2021 ;25,1:52-61
www.stabilis.org - 14/07/2022 01:11 - Page 10
Dictionary
Antibiotic InjectionTradename Stability in solutionsContainer MoleculeConcentration TemperatureStorage DurationBiosimilar Conflicting dataReferences Glass Water for Injection Protect from lightHour Not specifiedSodium chloride 0,9% Glucose 5%Ringer’s lactate solution Glucose 10%Polyethylene NaCl 0,9% or Glucose 5%Ethylene vinyl acetate DayNot specified Polyisoprene elastomerElastomer (unspecified) Factors which affect stabilitySolvent Parenteral nutrition (binary mixture)Induces DegradationNaHCO3 ReductionEnhanced stability CompatibilityCompound Chemical instabilityIncompatible Unspecified incompatibilityCompatible Parenteral nutrition (with lipids)Color change Precipitation after 1 hourImmediate turbidity Color change after 2 hoursImmediate precipitation Color change after 4 hoursNone Color change after 1 hourPrecipitation after 24 hours Turbidity in 4 hoursTurbidity in 24 hours Immediate instability of the emulsionPrecipitation after 4 hours Turbidity in one hourRoute of administration Intravenous infusion
www.stabilis.org - 14/07/2022 01:11 - Page 11
Intramuscular ReferencesDictionary
www.stabilis.org - 14/07/2022 01:11 - Page 12